Stereotactic Body Radiotherapy for Prostate Cancer
- 6 October 2021
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in American Journal of Clinical Oncology
- Vol. 44 (11), 553-558
- https://doi.org/10.1097/coc.0000000000000869
Abstract
Objectives: To provide an overview of the achievements and future research with stereotactic body radiotherapy (SBRT) in prostate cancer. Methods: SBRT publications for prostate cancer were retrieved from the Web of Science and Dimension database. Bibliometric analyses were performed using VOSviewer and Prism graph. Analysis of variance test was used to compare the publication, citation, and the mean citation between specialty journals. Network maps were produced to identify authors’ and countries’ collaboration clusters. Results: Between 2006 and 2020, 574 publications fulfilling the inclusion criteria were identified, and a significant growth trend in publication (PP=0.001) number was recognized over the period. The United States was the most productive country with 253 (44.2%) articles. The RED Journal had the highest number of publications (14%) and citations (19%). Urology journals published (P=0.01) and cited significantly less than radiation oncology journals (P=0.01). All open access and non–open access number of publications increased over time, with a significant difference between non–open access and open access journals (P<0.0001). Two author clusters were identified, in the United States with the collaboration of Canadian and British authors, and in Italy with the participation of European authors. Conclusion: The number of publications and citations on SBRT for prostate cancer has grown linearly in the last decades. The United States is the leading country in this research field, and the use of SBRT in oligometastatic disease, reirradiation, and salvage seems to be hot topics in this research field.Keywords
This publication has 22 references indexed in Scilit:
- Intensity‐modulated radiotherapy reduces toxicity with similar biochemical control compared with 3‐dimensional conformal radiotherapy for prostate cancer: A randomized clinical trialCancer, 2016
- Bibliometrics basicsJournal of the Medical Library Association, 2015
- Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinomaActa Oncologica, 2015
- Long-Term Outcomes From a Prospective Trial of Stereotactic Body Radiotherapy for Low-Risk Prostate CancerEndocrine, 2011
- Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung CancerJAMA, 2010
- Stereotactic Body Radiotherapy for Localized Prostate Cancer: Interim Results of a Prospective Phase II Clinical TrialEndocrine, 2009
- Incidence of Late Rectal and Urinary Toxicities After Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Localized Prostate CancerEndocrine, 2008
- Image-Guided Radiotherapy for Localized Prostate Cancer: Treating a Moving TargetSeminars in Radiation Oncology, 2008
- Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate CancerEndocrine, 2008
- Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trialThe Lancet, 1999